13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002010850
Total reported value
$731.7M
$731.7M
23 檔
66.3%
As reported in its official Q3 2025 Form 13F filing, Decheng Capital LLC's tracked investment portfolio stood at $731.7M with 23 total positions.
In Q3 2025, Decheng Capital LLC adopted a defensive or profit-taking posture, trimming 11 positions and completely liquidating 5 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including CGON, NUVB, UPB) accounted for 66.3% of total reported equity market value during Q3 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CGON | Cg Oncology Inc | Stock-Other | 44.78% | -3.34% | — | |
| 2 | NUVB | Nuvation Bio Inc | Stock-Other | 16.75% | +3.31% | — | |
| 3 | UPB | Upstream Bio Inc | Stock-Other | 10.78% | -1.13% | — | |
| 4 | AARD | Aardvark Therapeutics Inc | Stock-Other | 9.08% | +0.85% | — | |
| 5 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 3.26% | -0.75% | -14.67% | |
| 6 | ✓ | Merus N V | Stock-Other | 3.06% | — | -1.35% | |
| 7 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.71% | -0.03% | -7.08% | |
| 8 | LYEL | Lyell Immunopharma, Inc. | Stock-Other | 1.69% | -0.77% | — | |
| 9 | ✓ | Beyondspring Inc Shs | Stock-Other | 1.35% | -0.03% | -5.41% | |
| 10 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 1.34% | +0.63% | — | |
| 11 | RCUS | Arcus Biosciences Inc | Stock-Other | 1.30% | +0.40% | +242.26% | |
| 12 | EQ | Equillium Inc | Stock-Other | 1.11% | +0.60% | — | |
| 13 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.04% | — | — | |
| 14 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 0.99% | -0.29% | EXIT | |
| 15 | AURA | Aura Biosciences Inc | Stock-Other | 0.56% | — | — | |
| 16 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 0.35% | +0.41% | — | |
| 17 | ✓ | Moonlake Immunotherapeutics | Stock-Other | 0.23% | — | — | |
| 18 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.14% | — | -61.28% | |
| 19 | ILMN | Illumina Inc | Stock-Healthcare | 0.13% | — | — | |
| 20 | PYXS | Pyxis Oncology Inc | Stock-Other | 0.13% | +0.06% | — | |
| 21 | GRAL | Grail Inc | Stock-Healthcare | 0.10% | — | — | |
| 22 | RZLT | Rezolute Inc | Stock-Other | 0.10% | — | — | |
| 23 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.02% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | UPB | Upstream Bio Inc | +5.1% | — | Unchanged |
| 2 | NUVB | Nuvation Bio Inc | +3.9% | — | Unchanged |
| 3 | CGON | Cg Oncology Inc | +1% | — | Unchanged |
| 4 | AARD | Aardvark Therapeutics Inc | +0.8% | — | Unchanged |
| 5 | ✓ | Merus N V | +0.8% | -1.35% | Trim |
| 6 | EQ | Equillium Inc | +0.6% | — | Unchanged |
| 7 | PYXS | Pyxis Oncology Inc | 0% | — | Unchanged |
| 8 | GRAL | Grail Inc | 0% | — | Unchanged |
| 9 | NUVB-WS | Nuvation Bio Inc -cw27 | 0% | — | Unchanged |
| 10 | LYEL | Lyell Immunopharma, Inc. | -0.1% | — | Trim |
| 11 | ILMN | Illumina Inc | -0.1% | — | Trim |
| 12 | FDMT | 4d Molecular Therapeutics In | -0.2% | -61.28% | Trim |
| 13 | AURA | Aura Biosciences Inc | -0.3% | — | Unchanged |
| 14 | ACRS | Aclaris Therapeutics Inc | -0.4% | — | Unchanged |
| 15 | RCUS | Arcus Biosciences Inc | -0.5% | +242.26% | Trim |
| 16 | RVMD | Revolution Medicines Inc | -0.5% | -7.08% | Trim |
| 17 | ZNTL | Zentalis Pharmaceuticals Inc | -0.6% | — | Trim |
| 18 | ✓ | Beyondspring Inc Shs | -0.6% | -5.41% | Trim |
| 19 | CRNX | Crinetics Pharmaceuticals In | -0.6% | — | Trim |
| 20 | NAMS | NewAmsterdam Pharma Company N.V. | -1.2% | -14.67% | Trim |
| 21 | ✓ | Moonlake Immunotherapeutics | -1.7% | — | Add |
| 22 | KRYS | Krystal Biotech Inc | -2.3% | -51.06% | Trim |
| 23 | CYTK | Cytokinetics Inc | — | EXIT | Sold out |
| 24 | LEGN | Legend Biotech Corp-adr | — | EXIT | Sold out |
| 25 | ACLXGBX | Arcellx Inc | — | EXIT | Sold out |
| 26 | BNTX | Biontech Se-adr | — | EXIT | Sold out |
| 27 | RZLT | Rezolute Inc | — | NEW | New buy |
| 28 | VERA | Vera Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Decheng Capital LLC reported a total U.S. public equity portfolio value of $731.7M across 23 disclosed positions in Q3 2025.
During Q3 2025, Decheng Capital LLC's top holdings by market value included CGON (44.8%)、NUVB (16.8%)、UPB (10.8%). The largest single position, CGON, represented 44.8% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
RZLT
市值: $563.1K
Top Position Liquidated / Trimmed
CYTK
前期市值: $4.0M
In Q3 2025, Decheng Capital LLC made 18 total portfolio adjustments, initiating 1 new buys, adding to 1 positions, trimming 11 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.